The National Health Insurance Administration (NHIA) convened the 74th NHI Pharmaceutical Benefit and Reimbursement Scheme Joint Committee for Pharmaceuticals on March 28, 2025, and approved the inclusion of the new drug, vosoritide API (Active Pharmaceutical Ingredient), for the treatment of achondroplasia in the NHI payment package. Achondroplasia causes underdevelopment of the lower limbs and short upper limbs in patients, which may result in their dependence on others for daily activities, including even basic tasks such as going to the bathroom. This medication is currently the only available treatment for achondroplasia; it helps promote body growth, as well as improve torso length, head, and facial proportions. The yearly cost per patient for this medication is NT$7 million. The inclusion is expected to benefit approximately 72 patients annually, with an estimated NT$500 million in expenses covered by the rare disease special fund. This inclusion is set to take effect on May 1, 2025, at the earliest.